These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 11689387)
1. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Llach F; Yudd M Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408 [TBL] [Abstract][Full Text] [Related]
3. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662 [TBL] [Abstract][Full Text] [Related]
4. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251 [TBL] [Abstract][Full Text] [Related]
5. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Llach F; Keshav G; Goldblat MV; Lindberg JS; Sadler R; Delmez J; Arruda J; Lau A; Slatopolsky E Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143 [TBL] [Abstract][Full Text] [Related]
6. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802 [TBL] [Abstract][Full Text] [Related]
7. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study. Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518 [TBL] [Abstract][Full Text] [Related]
8. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664 [TBL] [Abstract][Full Text] [Related]
9. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024 [TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742 [TBL] [Abstract][Full Text] [Related]
11. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size. Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484 [TBL] [Abstract][Full Text] [Related]
12. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956 [TBL] [Abstract][Full Text] [Related]
13. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733 [TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. Capuano A; Serio V; Pota A; Memoli B; Andreucci VE J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819 [TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH; Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404 [TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
17. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806 [TBL] [Abstract][Full Text] [Related]
18. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Staniforth ME; Cheng SC; Coyne DW Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147 [TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Webb NJA; Lerner G; Warady BA; Dell KM; Greenbaum LA; Ariceta G; Hoppe B; Linde P; Lee HJ; Eldred A; Dufek MB Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]